tirzepatide into muscle Injections: How It Helps Treat Obesity Tirzepatide Injection Sites: Safe Administration

According to the SmPC and STEP clinical trials, these include: Nausea (affecting approximately 40-45% of patients) Vomiting (approximately 15-25% of patients) Diarrhoea (affecting approximately 25-30% of users) Constipation (approximately 20-25% of patients) Abdominal pain and bloating Gastro-oesophageal reflux For individuals taking oral anti-epileptic medications , severe or persistent vomiting could theoretically reduce drug absorption, potentially affecting seizure control

Despite these issues, there is no approved therapy to mitigate OM

The results of a two-year clinical trial, which will be available later this year, are expected to shed more light on the topic

V., Gerrard, J

Adjusting your dose upward follows evidence-based tolerability and efficacy data